Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy
- Resource Type
- Authors
- Janaki Amin; Brian Gazzard; Dianne Carey; Poh Lian Lim; Gwamaka Eliudi Mwasakifwa; Lerato Mohapi; Marcelo H. Losso; Mark A. Boyd; Jean-Michel Molina; Cecilia L. Moore; David A. Cooper; Paul Penteado
- Source
- AIDS. 32:357-361
- Subject
- 0301 basic medicine
medicine.medical_specialty
Multivariate analysis
030106 microbiology
Immunology
HIV Infections
Lopinavir
Plasma
03 medical and health sciences
0302 clinical medicine
Antiretroviral Therapy, Highly Active
Internal medicine
medicine
Humans
Immunology and Allergy
030212 general & internal medicine
Developing Countries
Chromatography, High Pressure Liquid
Retrospective Studies
business.industry
Proportional hazards model
Hazard ratio
HIV Protease Inhibitors
Odds ratio
Stepwise regression
Confidence interval
Regimen
Treatment Outcome
Infectious Diseases
Drug Monitoring
business
medicine.drug
- Language
- ISSN
- 0269-9370
BACKGROUND Resource constraints in low and middle-income countries necessitate practical approaches to optimizing antiretroviral therapy outcomes. We hypothesised that an untimed plasma lopinavir concentration (UPLC) at week 12 would predict loss of virological response in those taking lopinavir as part of a second-line antiretroviral regimen. METHODS We measured plasma lopinavir concentration at week 12 on stored samples from the SECOND-LINE study. We characterized UPLC as: detectable and optimal (≥1000 μg/l); detectable but suboptimal (≥25 to